Biomarkers Market - Global Trends & Forecasts (2013 – 2018)

By Author: Priyank Tiwari
Total Articles: 3
Comment this article

The global biomarkers market showcases high growth potential in the near future with an estimated CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. Current industry trends such as advancements in discovery technologies, government initiatives, and grants for biomarker research activities, and the rising demand for personalized medicine are the key factors that contribute to the growth of this market. However, the need for high capital investment for biomarker discovery, low benefit-cost ratio, a cumbersome biomarker validation, and testing process are a few of the critical factors that restrain the growth of the market.
The report categorizes the biomarkers market on the basis of discovery technologies (omics technology, imaging technology, and bioinformatics), biomarker services, applications, and disease indications. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally.
The emerging Asia-Pacific region exhibits high growth opportunities for industry participants. ...
... Growing economies such as China and India are experiencing an increasing rate of biomarkers research activities. This is attributed to the rising number of contract research organizations and the low cost of conducting clinical trials in Asia-Pacific nations when compared to developed countries. Increasing popularity of personalized medicine and the growing importance of companion diagnostics are further opening new growth opportunities for the development of novel biomarkers.
Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), GE Healthcare (U.K.), Affymetrix Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.) are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.
Key Take-Aways
• Definition, measurement, and forecast of the global biomarkers market on the basis of its discovery technologies, services, applications, and disease indications
• Detailed information regarding the major factors influencing the growth of the market (drivers, restraints, and industry specific challenges, among others)
• Strategic analysis of micro-markets with respect to individual growth trends, future prospects, and contribution to the total market
• Analyzing the opportunities in the market for stakeholders and details of a competitive landscape for market leaders
• Forecasting revenue of market segments with respect to four main geographies, namely, North America, Europe, Asia-Pacific, and Rest of the World
• Strategic profiling of key players and comprehensively analyzing their market shares and core competencies
• Tracking and analyzing competitive developments such as, joint ventures, mergers and acquisitions, new product developments, and research and development in the biomarkers market

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com